Agendia opens genomics lab in the US

25 May 2009

Agendia, a Dutch molecular cancer diagnostics firm, has opened a US clinical genomics laboratory in Huntington Beach, California. The  laboratory is fully-licensed and compliant with the Clinical Laboratory  Improvements Amendments as administered by the US Centers for Medicare  and Medicaid Services, the company stressed.

"Our enhanced domestic capabilities will help us to further drive  adoption of MammaPrint, and place us in an even better position to  collaborate with a growing number of clinical, academic, and industrial  partners here in the USA," said company chief executive Bernhard  Sixt.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight